The latest oncology news listed by date, covering all clinical focus areas, tumour types and more
ASCO 2016: PD-1 inhibitor pembrolizumab provides long-term survival benefit
Long-term follow-up from a phase Ib trial (KEYNOTE-001) in newly diagnosed and previously treated patients…